Anti Amyloid Leqembi denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Leqembi as "Duplicate Therapy" — and How to Appeal

A duplicate-therapy denial means Aetna's claims system identified another drug on your profile that it considers therapeutically equivalent to Leqembi (lecanemab). For anti-amyloid therapies, this logic is almost always flawed: Leqembi has a specific molecular target and mechanism, and no other currently approved drug for Alzheimer's disease works the same way. If Aetna's system flagged a symptomatic Alzheimer's medication as a duplicate, that is a clinical misclassification and a strong ground for appeal.

## Why This Denial Happens

Aetna's pharmacy benefit management system groups drugs by therapeutic category. If Leqembi was categorized alongside symptomatic cholinesterase inhibitors or NMDA antagonists — drugs that address symptoms rather than amyloid pathology — the system may generate a duplicate-therapy flag erroneously. The denial does not reflect a physician's clinical judgment; it is an automated benefit-management decision.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File a written appeal within the timeframe on your denial notice. The appeal must be reviewed under a full-and-fair standard by someone not involved in the initial denial.
• Expedited appeal: If your neurologist certifies that waiting poses a serious risk, Aetna must respond within 72 hours.
• External review: If Aetna upholds the denial, request independent external review within the four-month window following the final denial. External reviewers apply medical evidence standards, not formulary categorization logic, and routinely overturn mechanical duplicate-therapy denials.

## Documentation to Gather

1. Diagnosis confirmation — Records establishing early active Alzheimer's disease with confirmed amyloid pathology (PET scan or CSF biomarker report). 2. Current medication list — Obtain the full list of Alzheimer's-related medications Aetna has on file and identify the specific drug it flagged as a duplicate. 3. Mechanism-distinction letter — Ask the prescribing neurologist to write a letter explaining the mechanistic difference between Leqembi and the flagged drug, referencing the respective FDA-approved prescribing labels. 4. FDA label for Leqembi — Print the current label from the FDA website and highlight the indication and mechanism of action sections. 5. Aetna's clinical policy — Request Aetna's published coverage policy for Leqembi and the duplicate-therapy determination methodology.

## Criteria-Mapping Structure for Your Appeal

| Aetna's Duplicate Claim | Drug Flagged | Why It Is Not a Clinical Duplicate | |---|---|---| | Same therapeutic category | Per Aetna's system | FDA indication + mechanism comparison | | Same clinical outcome | Aetna's assumption | Neurologist letter on mechanistic distinction | | Patient receiving clinical benefit from current drug | Chart | Current cognitive/functional status documentation |

Demand that Aetna identify, in writing, the specific drug it considers a duplicate and the clinical basis for that equivalence finding. A failure to provide that basis is itself an appealable procedural defect.